Posted by Michael Wonder on 18 Sep 2019
Vertical Pharmaceuticals announces submission of new drug application for RVL-1201
17 September 2019 - Vertical Pharmaceuticals today announced the submission of a new drug application to the U.S. FDA for approval of RVL-1201 (RVL) for the treatment of acquired blepharoptosis (droopy eyelid).
RVL is a novel, once-daily ophthalmic formulation of oxymetazoline, a direct-acting α-adrenergic receptor agonist, which when administered to the eye is believed to selectively target Müller’s muscle and elevate the upper eyelid.
The submission is supported by a robust development program with compelling safety and efficacy data from three well-controlled pivotal studies – two efficacy and one extended-duration safety trial.
